Drugs / rVSVN4CT1-EBOVGP1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02718469 | Dec 2015 → Sep 2016 | Ebola hemorrhagic fever | Auro Vaccines LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rVSVN4CT1-EBOVGP1 | “A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Monovalent Ebola Zaire Vaccine (rVSVN4CT1-EBOVGP1) Delivered by Intramuscular Injection in Healthy Adult Subjects” NCT02718469 ↗ |
| Known as | Ebola Zaire Vaccine | “A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Monovalent Ebola Zaire Vaccine (rVSVN4CT1-EBOVGP1) Delivered by Intramuscular Injection in Healthy Adult Subjects” NCT02718469 ↗ |
| Modality | Vaccine | “a Monovalent Ebola Zaire Vaccine” NCT02718469 ↗ |
| Route | Intramuscular | “Delivered by Intramuscular Injection” NCT02718469 ↗ |